Non-small cell lung cancer patients are treated differently, depending largely on histology identification of squamous vs. adenocarcinoma subtypes. This distinction has been classically based on micro-morphology features, but immunohistochemistry (IHC) has become a major tool for this distinction in recent years. We retrospectively compared the outcome of adenocarcinoma patients considering their diagnosis being based on morphology versus IHC. We found the method of diagnosis to be an independent prognostic factor. We believe that identification of adenocarcinoma as based on morphology vs. IHC should be integrated into the evaluation of such patients and should be considered as a stratification factor in clinical trials.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jX4K8s
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου